Data completeness
0/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUDAFED 12 HOUR is an extended-release oral capsule containing an unknown active ingredient developed by GSK for nasal/sinus decongestant indications. The mechanism of action and pharmacologic class are not currently disclosed in available data. This small-molecule product is positioned as a convenient 12-hour dosing alternative in the over-the-counter decongestant market.
Pre-Launch
Pre-launch stage indicates active recruitment for launch infrastructure, including brand, field, and medical affairs teams preparing for market entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SUDAFED 12 HOUR offers a launch-stage opportunity in a stable, high-volume OTC category, providing early career exposure to full commercial lifecycle planning. However, the OTC decongestant market is mature and price-competitive, so differentiation and rapid market capture are critical to team growth and long-term brand stability.
Brand ManagerField Sales Representative
Worked on SUDAFED 12 HOUR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.